Thermo Fisher Scientific Raises Outlook, Forecasts Strong Growth in 2026
Thermo Fisher Scientific (TMO) reported a return to organic growth of 5% in the second quarter and raised its full-year outlook. CEO Marc Casper expects approximately 4% organic growth for 2026, calling it an 'outstanding year.' The company cited stronger demand from pharmaceuticals and biotechnology sectors driven by increased investment in drug development pipelines, AI integration, and emerging therapies. Casper highlighted that improved venture capital funding, M&A activity, and IPOs are boosting spending across clinical research, lab supplies, and bioproduction. Additionally, U.S. pharmaceutical reshoring efforts could provide growth through 2028 via domestic CDMO contracts and new manufacturing facilities. Long-term support is also expected from stabilizing academic markets and improving demand in China.
Tickers: $TMO
Topics: biotech demand growth executive commentary organic revenue pharma